{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Breast+cancer+surgery", "query": { "intervention": "Breast cancer surgery" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1034, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Breast+cancer+surgery&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-11T23:02:38.987Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05949021", "title": "OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "Combination of liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mridula George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 30, "start_date": "2023-10-07", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 8, "location_summary": "Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 3 more", "locations": [ { "city": "Elizabeth", "state": "New Jersey" }, { "city": "Jersey City", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05949021" }, { "nct_id": "NCT02701244", "title": "A Registry Study of Breast Microseed Treatment", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Permanent Breast Seed Implant (PBSI)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Concure Oncology-Breast Microseed Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 420, "start_date": "2016-07", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2018-03-19", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 3, "location_summary": "Pittsburgh, Pennsylvania • Fredericksburg, Virginia • Seattle, Washington", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Fredericksburg", "state": "Virginia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02701244" }, { "nct_id": "NCT00002616", "title": "Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "ALL", "summary": "Up to 64 Years" }, "enrollment_count": 36, "start_date": "1995-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002616" }, { "nct_id": "NCT03044730", "title": "Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-05-25", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 2, "location_summary": "Chicago, Illinois • Lake Forest, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03044730" }, { "nct_id": "NCT04331067", "title": "Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Cabiralizumab", "type": "BIOLOGICAL" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Bone marrow", "type": "PROCEDURE" }, { "name": "Blood draw", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-11-19", "completion_date": "2026-06-09", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04331067" }, { "nct_id": "NCT02380209", "title": "An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CEST MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2014-08", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-10-27", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02380209" }, { "nct_id": "NCT04427293", "title": "Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2020-07-09", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04427293" }, { "nct_id": "NCT01334021", "title": "Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Genetic Testing", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1100, "start_date": "2011-05-31", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334021" }, { "nct_id": "NCT06966700", "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Triple Negative Breast Neoplasms", "HR Low-Positive/HER2-Negative Breast Neoplasms" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2400, "start_date": "2025-06-30", "completion_date": "2034-12-29", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 63, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06966700" }, { "nct_id": "NCT04549571", "title": "Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage 0 Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8" ], "interventions": [ { "name": "Decision Aid iCanDecide - ESE website", "type": "OTHER" }, { "name": "Decision Aid iCanDecide - S website", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Interview", "type": "OTHER" }, { "name": "Training", "type": "OTHER" }, { "name": "Media Intervention", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 543, "start_date": "2021-02-16", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-10-11T23:02:38.987Z", "location_count": 27, "location_summary": "Vallejo, California • Newark, Delaware • Rehoboth Beach, Delaware + 23 more", "locations": [ { "city": "Vallejo", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Rehoboth Beach", "state": "Delaware" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT04549571" } ] }